Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 20.5% in the afternoon session after the company reported weak first quarter 2025 results which featured drastically lowered full ...

Can investing in Sarepta Therapeutics help make you a millionaire? Over the past five years, Sarepta's stock has been a disappointment, falling by 30% in value.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the ...